Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Terminated 2Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Sarcoma 2

Conditions

Sarcoma 172Glioblastoma 72Gliosarcoma 70Brain Neoplasms 41Osteosarcoma 40Neoplasms 40Astrocytoma 38Recurrence 35Melanoma 33Oligodendroglioma 32Gastrointestinal Stromal Tumors 31Breast Neoplasms 31Glioma 30Lymphoma 29Dendritic Cell Sarcoma, Interdigitating 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Neoplasm Metastasis 28Central Nervous System Neoplasms 27Burkitt Lymphoma 26Bone Neoplasms 26Ovarian Neoplasms 25Colorectal Neoplasms 24Neuroblastoma 22Lymphoma, Non-Hodgkin 22Lymphoma, Large B-Cell, Diffuse 22Stomach Neoplasms 21Sarcoma, Ewing 21Lung Neoplasms 19Leukemia, Myeloid, Acute 19Leukemia 19

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neurofibromatoses × Sarcoma × Clear all
NCT05011019 2024-03-21

A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Terminated
22 enrolled
CNSSarcoma

Neurofibromatoses, Neurofibrosarcoma

NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Novartis

Phase 2/3 Terminated
11 enrolled
CNSSarcoma

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡